Jade Biosciences
JBIO
64 hedge funds and large institutions have $639M invested in Jade Biosciences in 2023 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 21 increasing their positions, 15 reducing their positions, and 4 closing their positions.
175% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 4
65% more capital invested
Capital invested by funds: $386M → $639M (+$252M)
40% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 15
10% more funds holding
Funds holding: 58 → 64 (+6)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
0.03% less ownership
Funds ownership: 2.94% → 2.91% (-0.03%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.43M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
+$2.09M |
| 3 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$1.56M |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$1.5M |
| 5 |
Morgan Stanley
New York
|
+$743K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$5.1M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$4.12M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$1.88M |
| 4 |
OCA
Octagon Capital Advisors
New York
|
-$1.36M |
| 5 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$1.36M |
JBIO Hedge Fund Activity: Q4 2023 in Review
64 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Jade Biosciences (JBIO) for Q4 2023, worth a combined $639M — up 65% from $386M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new JBIO positions and 4 closed out — a net gain of 7 holders — while 21 added to existing stakes and 15 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $6.43M. The largest seller was Cormorant Asset Management, cutting an estimated $5.1M.
- 64 institutional investors held Jade Biosciences (JBIO) as of Q4 2023, up from 58 in Q3 2023.
- Funds reported $639M of Jade Biosciences stock for Q4 2023, up 65% quarter-over-quarter.
- 11 funds opened new Jade Biosciences positions in Q4 2023 and 4 closed out, a net change of +7 holders.
- The largest Jade Biosciences buyer in Q4 2023 was Point72 Asset Management, an estimated $6.43M added.
- The largest Jade Biosciences seller in Q4 2023 was Cormorant Asset Management, an estimated $5.1M sold.
Based on aggregated 13F filings for Q4 2023.